What Osteal Therapeutics does

Osteal Therapeutics is a clinical-stage specialty biopharmaceutical company developing novel drug/device combination treatments for orthopedic infections, with its lead program focused on periprosthetic joint infection (PJI) of the hip and knee following joint replacement surgery. The company's flagship product, NEXCHANGE KIT (formerly VT-X7), combines a proprietary spacer device with the CLEAR protocol—a 7-day cyclic irrigation regimen that delivers therapeutic concentrations of vancomycin and tobramycin directly to the joint space before reimplantation of a permanent prosthesis. The clinical program targets a clear unmet need: PJI affects more than 40,000 US patients annually, and the current standard of care (two-stage exchange arthroplasty) requires roughly 16 weeks of treatment with success rates below 50% at 12 months and substantial patient morbidity. In the APEX pivotal program (152 patients across 23 US centers), VT-X7 demonstrated a 41% net treatment effect at six months, a 19% net treatment effect at 12 months, a 71% reduction in PJI burden versus standard of care, and enabled 100% of treated patients to receive a permanent implant within seven days versus 61.6% under standard care.

The product is protected by 12 US patents and four FDA designations (Breakthrough Therapy, Orphan Drug, Fast Track, and Qualified Infectious Disease Product). Osteal is pre-revenue and operates a single-product, single-indication business model: post-approval, revenue will be generated through direct hospital and surgical center sales of the combination product to orthopedic surgeons and joint replacement specialists performing revision arthroplasty. The go-to-market motion combines enterprise field sales (VP of Sales hired November 2025) with event-driven clinical data dissemination at AAHKS, MSIS, and EBJIS conferences, supported by peer-to-peer KOL education and an Expanded Access Program. Founded in 2012 and headquartered in Dallas, TX, Osteal has raised more than $100 million across Series B ($30M, 2022), Series C ($23M, 2023), and Series D ($50M, 2024) rounds from a syndicate including Zimmer Biomet, Johnson & Johnson Development Corporation, HM Capital, Asteroid Partners, Gideon Strategic Partners, Prism Ventures, and Medvest Capital.

Name

Osteal Therapeutics

Legal name

Osteal Therapeutics, Inc.

Website

https://ostealtx.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Osteal Therapeutics is a clinical-stage biopharmaceutical company developing NEXCHANGE KIT, a drug/device combination for treating periprosthetic joint infections following joint replacement surgery, targeting orthopedic surgeons and hospitals in the United States.

Ownership category

akta.pro rank

Product category

Orthopedic Infection Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral) (HLAAAEAF), DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms (HLACANAM)

Keywords

• Orthopedic infection therapeutics
• Drug device combination
• Periprosthetic joint infection
• Musculoskeletal therapeutics
• Local antibiotic irrigation

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. NEXCHANGE KIT (VT-X7) Product Sales: Revenue from sale of drug/device combination product for PJI treatment. Once FDA approved, the company will commercialize through hospital and surgical center sales channels targeting orthopedic surgeons performing joint replacement revision surgeries.
2. Future Pharmaceutical Product Revenue: Pre-revenue clinical stage company. Revenue model will be based on product sales of FDA-approved drug/device combination therapy for orthopedic infections.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Osteal Therapeutics develops NEXCHANGE KIT (formerly VT-X7), a drug-device combination product for treating periprosthetic joint infection (PJI) of the hip and knee following joint replacement surgery. The product combines a specialized NEXCHANGE Spacer with vancomycin and tobramycin delivered via the proprietary CLEAR™ protocol over 7 days to resolve infection and enable reimplantation of a permanent prosthesis. The product has received FDA Breakthrough Therapy, Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations, and if approved would be the first therapy specifically indicated for PJI.

Product overview

Osteal Therapeutics is developing NEXCHANGE™ KIT (formerly known as VT-X7), a novel drug-device combination product for treating periprosthetic joint infection (PJI). The product combines a specialized spacer and fluid management dressing with an irrigation pump to deliver high-concentration antibiotics (vancomycin and tobramycin) directly to the infected joint space using the CLEAR™ protocol over a 7-day treatment period. The company employs a low-risk development strategy using approved drugs with established safety histories for new routes of local delivery. NEXCHANGE KIT is currently in late-stage clinical development (APEX and APEX-2 trials) and has received FDA Breakthrough Therapy, Orphan Drug, Fast Track, and Qualified Infectious Disease Product designations.

Differentiator

Problem solved

Functional benefit

Products and services

• NEXCHANGE KIT (formerly VT-X7) A drug-device combination product (formerly known as VT-X7) designed for local antibiotic delivery to treat infected joint prosthesis in periprosthetic joint infection (PJI) of the hip and knee. Delivers therapeutic concentrations of vancomycin and tobramycin directly to the joint space and surrounding tissue via the proprietary CLEAR™ (Cyclic, Local, Expedited, Antibiotic-Irrigation Regimen) protocol over 7 days before reimplantation of a permanent prosthesis. Intended for orthopedic surgeons and hospitals performing revision arthroplasty in patients with PJI following joint replacement surgery.

Quantifiable outcome

• 100% of VT-X7 patients received permanent joint prosthesis in 7 days versus 61.6% of control patients at one year
• +4 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Cleveland Clinic FoundationcoreStrategic or Co-development PartnerDr. Nicolas S. Piuzzi from Cleveland Clinic serves as Principal Investigator for APEX and APEX-2 clinical studies. Key opinion leader in musculoskeletal infection treatment providing clinical trial leadership.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Vericel: Vericel develops specialty biologics for orthopedic and sports medicine indications (MACI for cartilage repair, NexoBrid for burns). Comparable to Osteal as a US specialty pharma/biotech focused on orthopedic surgical applications with concentrated hospital/surgeon customer bases and similar commercial build-out challenges.
• Anika Therapeutics: Anika develops intra-articular hyaluronic acid therapies (Monovisc, Orthovisc, Cingal) and regenerative orthopedic products. Comparable to Osteal as a specialty orthopedic pharma targeting joint preservation/repair via novel intra-articular delivery mechanisms sold to orthopedic surgeons.
• Pacira BioSciences: Pacira acquired Flexion Therapeutics (Zilretta, an intra-articular corticosteroid for OA knee pain) and focuses on non-opioid pain management via localized drug delivery. Comparable to Osteal in its strategy of replacing systemic or surgical standards of care with targeted local delivery in joint-related indications.

Emerging players

• Spero Therapeutics: Spero Therapeutics is a clinical-stage antibiotics developer focused on multidrug-resistant infections. Comparable to Osteal as a specialty anti-infective developer using novel mechanisms and formulations to address serious bacterial infections in defined patient populations.
• Melinta Therapeutics: Melinta (now owned by Dechra) develops and commercializes antibiotics for serious and life-threatening infections, including hospital-administered products. Comparable to Osteal in its specialty anti-infective focus and hospital-channel commercialization approach.
• MiMedx: MiMedx develops regenerative orthobiologics (EpiFix, AmnioFix) for wound care and musculoskeletal applications. Comparable to Osteal as a specialty orthopedic/wound care company selling to surgeons and hospitals with novel biological/device combination products.
• Bioventus: Bioventus offers orthobiologics and pain management solutions (joint fluid therapies like Supartz, bone graft substitutes) sold to orthopedic specialists. Comparable to Osteal in serving the orthopedic surgical channel with combination products addressing musculoskeletal conditions.

Broad incumbents

• Zimmer Biomet: Zimmer Biomet is a global leader in knee/hip implants and revision arthroplasty systems, and a strategic investor in Osteal (Series D lead, board seat). Comparable as the dominant orthopedic device incumbent in PJI-adjacent revision surgery, and a likely commercial partner post-approval.
• Smith & Nephew: Smith & Nephew is a diversified orthopedic and wound management company with significant knee/hip reconstruction, trauma, and advanced wound care franchises (including antimicrobial dressings used in infection management). Comparable as a broad incumbent operating in both orthopedic surgical and infection-adjacent wound care markets.
• Stryker: Stryker is a global orthopedic and medical device leader with knee/hip implant systems and infection-related surgical products (including antibiotic-loaded bone cement). Comparable as a broad incumbent competing in PJI-adjacent revision surgery and surgical infection prevention.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/osteal

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds6 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Osteal Therapeutics